Use of systematic evidence maps within the US Environmental Protection Agency (EPA) Integrated Risk Information System (IRIS) program: Advancements to date and looking ahead

Thayer, Kristina A.; Shaffer, Rachel M.; Angrish, Michelle; Arzuaga, Xabier; Carlson, Laura M.; Davis, Allen P.; Dishaw, Laura; Druwe, Ingrid; Gibbons, Catherine F.; Glenn, Barbara; Jones, Ryan; Kaiser, Jonas; Keshava, Channa; Keshava, Nagalakshmi; Kraft, Andrew D.; Lizarraga, Lucina E.; Markey, Kristan; Persad, Amanda S.; Radke, Elizabeth G.; Rice, Glenn; Schulz, Brittany; Shannon, Teresa; Shapiro, A. M. James; Thacker, Shane; Vulimiri, Suryanarayana V.; Woodall, George M.; Yost, Erin E.

doi:10.1016/j.envint.2022.107363

Cited by 5 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Office of Research and Development (ORD) Staff Handbook for Developing IRIS Assessments (referred to as the “IRIS Handbook”) 27 and a published evidence map template 28 , 29 outlines the systematic review methods used to develop the evidence map. The methods reproduced below are taken directly from our earlier SEMs on

PFAS, 12 , 30 because this SEM is a continuation of that work.…”

Section: Methodsmentioning

confidence: 99%

Expanded Systematic Evidence Map for Hundreds of Per- and Polyfluoroalkyl Substances (PFAS) and Comprehensive PFAS Human Health Dashboard

Shirke,

Radke,

Lin

et al. 2024

Environ Health Perspect

Self Cite

View full text Add to dashboard Cite

Background: Per- and polyfluoroalkyl substances (PFAS) encompass a class of chemically and structurally diverse compounds that are extensively used in industry and detected in the environment. The US Environmental Protection Agency (US EPA) 2021 PFAS Strategic Roadmap describes national research plans to address the challenge of PFAS. Objectives: Systematic Evidence Map (SEM) methods were used to survey and summarize available epidemiological and mammalian bioassay evidence that could inform human health hazard identification for a set of 345 PFAS that were identified by the US EPA’s Center for Computational Toxicology and Exposure (CCTE) for in vitro toxicity and toxicokinetic assay testing and through interagency discussions on PFAS of interest. This work builds from the 2022 evidence map that collated evidence on a separate set of PFAS. Like our previous work, this SEM does not include PFAS that are the subject of ongoing or completed assessments at the US EPA. Methods: SEM methods were used to search, screen, and inventory mammalian bioassay and epidemiological literature from peer-reviewed and gray literature sources using manual review and machine-learning software. For each included study, study design details and health end points examined were summarized in interactive web-based literature inventories. Some included studies also underwent study evaluation and detailed extraction of health end point data. All underlying data is publicly available online as interactive visuals with downloadable metadata. Results: More than 13,000 studies were identified from scientific databases. Screening processes identified 121 mammalian bioassay and 111 epidemiological studies that met screening criteria. Epidemiological evidence (available for 12 PFAS) mostly assessed the reproductive, endocrine, developmental, metabolic, cardiovascular, and immune systems. Mammalian bioassay evidence (available for 30 PFAS) commonly assessed effects in the reproductive, whole-body, nervous, and hepatic systems. Overall, 41 PFAS had evidence across mammalian bioassay and epidemiology data streams (roughly 11% of searched chemicals). Discussion: No epidemiological and/or mammalian bioassay evidence were identified for most of the PFAS included in our search. Results from this SEM, our 2022 SEM on PFAS, and other PFAS assessment products from the US EPA are compiled into a comprehensive PFAS dashboard that provides researchers and regulators an overview of the current PFAS human health landscape including data gaps and can serve as a scoping tool to facilitate prioritization of PFAS-related research and/or risk assessment activities. https://doi.org/10.1289/EHP13423

show abstract

PFAS, 12 , 30 because this SEM is a continuation of that work.…”

Section: Methodsmentioning

confidence: 99%

Expanded Systematic Evidence Map for Hundreds of Per- and Polyfluoroalkyl Substances (PFAS) and Comprehensive PFAS Human Health Dashboard

Shirke,

Radke,

Lin

et al. 2024

Environ Health Perspect

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition to confirming that studies met PECO criteria, the health endpoints investigated in each study were identified using structured forms in litstream. Health endpoints were organized by organ/system as outlined in ( Thayer et al, 2022 ): Cardiovascular, Dermal, Developmental, Endocrine, Gastrointestinal, Hematopoietic, Hepatobiliary, Immune System, Metabolic, Musculoskeletal, Nervous System, Ocular, Reproductive, Respiratory, and Urinary System. These categories were chosen because of their potential to include specific noncancer health endpoints that could be affected by PCB exposure at levels relevant to those experienced in the general population.…”

Section: Methodsmentioning

confidence: 99%

A systematic evidence map for the evaluation of noncancer health effects and exposures to polychlorinated biphenyl mixtures

Carlson

Christensen

Sagiv

et al. 2023

Environmental Research

Self Cite

View full text Add to dashboard Cite

Application of systematic evidence mapping to identify available data on the potential human health hazards of selected market-relevant azo dyes

Keshava

Nicolai

Vulimiri

et al. 2023

Environment International

View full text Add to dashboard Cite

Use of systematic evidence maps within the US Environmental Protection Agency (EPA) Integrated Risk Information System (IRIS) program: Advancements to date and looking ahead

Cited by 5 publications

References 15 publications

Expanded Systematic Evidence Map for Hundreds of Per- and Polyfluoroalkyl Substances (PFAS) and Comprehensive PFAS Human Health Dashboard

Expanded Systematic Evidence Map for Hundreds of Per- and Polyfluoroalkyl Substances (PFAS) and Comprehensive PFAS Human Health Dashboard

A systematic evidence map for the evaluation of noncancer health effects and exposures to polychlorinated biphenyl mixtures

Application of systematic evidence mapping to identify available data on the potential human health hazards of selected market-relevant azo dyes

Contact Info

Product

Resources

About